Jump to Navigation

Facebook Connect

User login

CETP Inhibition - An Important Potential Strategy in Reducing Cardiovascular Events

CETP Inhibition - An Important Potential Strategy in Reducing Cardiovascular Events


Schedule: On Demand (The original live program aired on Thursday, September 6, 2012)

Program Overview:
In large landmark trials, reduction in low-density lipoprotein cholesterol (LDL-C) levels with statins has been shown to decrease the incidence of major cardiovascular events by 25-45%. However, considerable residual risk remains even with an aggressive statin regimen. New therapeutic options are clearly needed to further improve the treatment of atherogenic dyslipidemia by reducing residual cardiovascular risk. A case can be made that strategies designed to reduce the risk of atherosclerotic cardiovascular disease should include both lowering the level of LDL-Cholesterol and raising that of HDL-Cholesterol. One strategy is to inhibit Cholesterol ester transfer protein (CETP). CETP inhibition in humans increases the concentration of cholesterol in the potentially protective HDL fraction while decreasing in the harmful non-HDL fractions. This discussion will focus on the mechanism of action of CETP inhibitors. What is known about the relationship between CETP and atherosclerosis? The genetic and experimental evidence will be presented. The clinical trial evidence will be reviewed. Is there is a compelling case for further testing the hypothesis? Join Drs. J. Antonio G. Lopez, Eliot A. Brinton, and Benjamin J. Ansell as they debate CETP inhibition strategies.

Moderator:
J. Antonio G. López, MD, FACC, FAHA, FACP, FASH, FNLA

President, Pacific Lipid Association
Director, Preventive Cardiology and Cardiovascular Rehabilitation
Director, Lipid Clinic and LDL Apheresis Program
Saint Alphonsus Regional Medical Center
Boise, ID

Protagonist:
Eliot A. Brinton, MD, FNLA

Associate Professor
Cardiovascular Genetics
University of Utah School of Medicine
Salt Lake City, UT

Antagonist: Benjamin J. Ansell, MD, FACP, FACC, FNLA
Associate Clinical Professor of Medicine
Co-Director, UCLA Cholesterol Hypertension & Atherosclerosis Management Program (CHAMP)
Los Angeles, CA

Technical Support

This program requires a current version of ONE of the following web browsers, with JavaScript enabled:

  • Google Chrome
  • Firefox 5.0 or greater
  • Safari
  • Internet Explorer 8.0 or greater

This NLA Lipid Insights Archive Program is Mobile Device friendly. If you experience difficulty viewing the video portion of this program, please contact us.

The handouts portion of this program requires the Adobe Acrobat Reader or a similar PDF program. You probably already have it; but if you cannot view the handouts, you can obtain the Adobe Acrobat Reader here.

If you require assistance to view/hear this program, please contact us.

4
Average: 4 (1 vote)

Education Information

This program, though not accredited in its archived form, is targeted towards specific content areas and learning objectives.



Content Domain
This activity falls under the following content domain(s):

  • 1.2.1.7.1 Cholesteryl ester transfer protein (CETP)

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism



by Dr. Radut.